Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Research output: Contribution to journal › Review › Research › peer-review

Standard

Rare dyslipidaemias, from phenotype to genotype to management : a European Atherosclerosis Society task force consensus statement. / Hegele, Robert A.; Borén, Jan; Ginsberg, Henry N.; Arca, Marcello; Averna, Maurizio; Binder, Christoph J.; Calabresi, Laura; Chapman, M. John; Cuchel, Marina; von Eckardstein, Arnold; Frikke-Schmidt, Ruth; Gaudet, Daniel; Hovingh, G. Kees; Kronenberg, Florian; Lütjohann, Dieter; Parhofer, Klaus G.; Raal, Frederick J.; Ray, Kausik K.; Remaley, Alan T.; Stock, Jane K.; Stroes, Erik S.; Tokgözoğlu, Lale; Catapano, Alberico L.

In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 1, 01.2020, p. 50-67.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Hegele, RA, Borén, J, Ginsberg, HN, Arca, M, Averna, M, Binder, CJ, Calabresi, L, Chapman, MJ, Cuchel, M, von Eckardstein, A, Frikke-Schmidt, R, Gaudet, D, Hovingh, GK, Kronenberg, F, Lütjohann, D, Parhofer, KG, Raal, FJ, Ray, KK, Remaley, AT, Stock, JK, Stroes, ES, Tokgözoğlu, L & Catapano, AL 2020, 'Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement', The Lancet Diabetes and Endocrinology, vol. 8, no. 1, pp. 50-67. https://doi.org/10.1016/S2213-8587(19)30264-5

APA

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., Frikke-Schmidt, R., Gaudet, D., Hovingh, G. K., Kronenberg, F., Lütjohann, D., Parhofer, K. G., Raal, F. J., Ray, K. K., Remaley, A. T., ... Catapano, A. L. (2020). Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. The Lancet Diabetes and Endocrinology, 8(1), 50-67. https://doi.org/10.1016/S2213-8587(19)30264-5

Vancouver

Hegele RA, Borén J, Ginsberg HN, Arca M, Averna M, Binder CJ et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. The Lancet Diabetes and Endocrinology. 2020 Jan;8(1):50-67. https://doi.org/10.1016/S2213-8587(19)30264-5

Author

Hegele, Robert A. ; Borén, Jan ; Ginsberg, Henry N. ; Arca, Marcello ; Averna, Maurizio ; Binder, Christoph J. ; Calabresi, Laura ; Chapman, M. John ; Cuchel, Marina ; von Eckardstein, Arnold ; Frikke-Schmidt, Ruth ; Gaudet, Daniel ; Hovingh, G. Kees ; Kronenberg, Florian ; Lütjohann, Dieter ; Parhofer, Klaus G. ; Raal, Frederick J. ; Ray, Kausik K. ; Remaley, Alan T. ; Stock, Jane K. ; Stroes, Erik S. ; Tokgözoğlu, Lale ; Catapano, Alberico L. / Rare dyslipidaemias, from phenotype to genotype to management : a European Atherosclerosis Society task force consensus statement. In: The Lancet Diabetes and Endocrinology. 2020 ; Vol. 8, No. 1. pp. 50-67.

Bibtex

@article{6b8103ed48b1436981095bc0be769a68,
title = "Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement",
abstract = "Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.",
author = "Hegele, {Robert A.} and Jan Bor{\'e}n and Ginsberg, {Henry N.} and Marcello Arca and Maurizio Averna and Binder, {Christoph J.} and Laura Calabresi and Chapman, {M. John} and Marina Cuchel and {von Eckardstein}, Arnold and Ruth Frikke-Schmidt and Daniel Gaudet and Hovingh, {G. Kees} and Florian Kronenberg and Dieter L{\"u}tjohann and Parhofer, {Klaus G.} and Raal, {Frederick J.} and Ray, {Kausik K.} and Remaley, {Alan T.} and Stock, {Jane K.} and Stroes, {Erik S.} and Lale Tokg{\"o}zoğlu and Catapano, {Alberico L.}",
year = "2020",
month = jan,
doi = "10.1016/S2213-8587(19)30264-5",
language = "English",
volume = "8",
pages = "50--67",
journal = "The Lancet Diabetes & Endocrinology",
issn = "2213-8587",
publisher = "The Lancet Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Rare dyslipidaemias, from phenotype to genotype to management

T2 - a European Atherosclerosis Society task force consensus statement

AU - Hegele, Robert A.

AU - Borén, Jan

AU - Ginsberg, Henry N.

AU - Arca, Marcello

AU - Averna, Maurizio

AU - Binder, Christoph J.

AU - Calabresi, Laura

AU - Chapman, M. John

AU - Cuchel, Marina

AU - von Eckardstein, Arnold

AU - Frikke-Schmidt, Ruth

AU - Gaudet, Daniel

AU - Hovingh, G. Kees

AU - Kronenberg, Florian

AU - Lütjohann, Dieter

AU - Parhofer, Klaus G.

AU - Raal, Frederick J.

AU - Ray, Kausik K.

AU - Remaley, Alan T.

AU - Stock, Jane K.

AU - Stroes, Erik S.

AU - Tokgözoğlu, Lale

AU - Catapano, Alberico L.

PY - 2020/1

Y1 - 2020/1

N2 - Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

AB - Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

U2 - 10.1016/S2213-8587(19)30264-5

DO - 10.1016/S2213-8587(19)30264-5

M3 - Review

C2 - 31582260

AN - SCOPUS:85074768982

VL - 8

SP - 50

EP - 67

JO - The Lancet Diabetes & Endocrinology

JF - The Lancet Diabetes & Endocrinology

SN - 2213-8587

IS - 1

ER -

ID: 244525623